Theo Koritzinsky

Theo Koritzinsky. He is a prominent Norwegian molecular biologist and cancer researcher, best known for his groundbreaking work on how tumors adapt to low-oxygen environments, a condition known as hypoxia. His research has significantly advanced the understanding of cancer metabolism and cellular stress response pathways, with implications for developing new therapeutic strategies. Koritzinsky has spent his career at leading institutions in Oslo, including the University of Oslo and Oslo University Hospital, where he leads a major research group.

Early life and education

Born in Oslo in 1965, he developed an early interest in the biological sciences. He pursued his higher education at the University of Oslo, where he completed a cand.scient. degree in molecular biology. His doctoral research, conducted at the same institution under the supervision of Professor Kirsten Sandvig, focused on intracellular transport and toxin action. He earned his PhD from the University of Oslo in 1999, laying a foundational expertise in cell biology that would later inform his cancer research.

Academic career

Following his doctorate, he sought postdoctoral training abroad to specialize in cancer biology. He joined the laboratory of Professor Bradly G. Wouters at the Ontario Cancer Institute, part of the University Health Network in Toronto, Canada. This fellowship, supported by the Norwegian Cancer Society, was pivotal in shifting his research focus toward tumor hypoxia. Returning to Norway, he established his independent research group at the Institute for Cancer Research within the Oslo University Hospital and the University of Oslo. He has held positions as a senior scientist and group leader, contributing significantly to the Norwegian Radium Hospital research community and mentoring numerous PhD candidates and postdoctoral fellows.

Research and contributions

His laboratory's primary research investigates the molecular mechanisms that allow cancer cells to survive and proliferate under the hypoxic conditions commonly found within solid tumors. A major contribution has been the elucidation of how hypoxia reprograms protein synthesis and induces the unfolded protein response in the endoplasmic reticulum. His team has published key studies in high-impact journals like Nature Communications, Cancer Research, and the PNAS on topics such as translational control, DNA damage response, and autophagy in hypoxic tumors. This work is crucial for understanding treatment resistance to modalities like radiotherapy and chemotherapy, and it identifies potential targets for novel cancer therapy.

Awards and honors

In recognition of his scientific achievements, he was awarded the prestigious King Olav V's Prize for Cancer Research in 2010. His research has been consistently funded by competitive grants from organizations such as the Norwegian Cancer Society, the Research Council of Norway, and the European Research Council. He is a frequent invited speaker at international conferences, including those organized by the American Association for Cancer Research, and serves on the editorial boards of several specialized journals in the field of cancer biology.

Personal life

He maintains a private life centered in Oslo. Colleagues describe him as a dedicated and collaborative scientist deeply committed to advancing cancer research in Norway and fostering the next generation of researchers. Outside the laboratory, he has interests in outdoor activities common to the Norwegian landscape.

Category:Norwegian molecular biologists Category:Norwegian cancer researchers Category:University of Oslo alumni Category:University of Oslo faculty Category:1965 births Category:Living people